Ryan J Soose1, B Tucker Woodson2, M Boyd Gillespie3, Joachim T Maurer4, Nico de Vries5, David L Steward6, Kingman P Strohl7, Jonathan Z Baskin7, Tapan A Padhya8, M Safwan Badr9, Ho-sheng Lin9, Olivier M Vanderveken10, Sam Mickelson11, Eileen Chasens12, Patrick J Strollo1. 1. University of Pittsburgh School of Medicine, Pittsburgh, PA. 2. Medical College of Wisconsin, Milwaukee, WI. 3. Medical University of South Carolina, Charleston, SC. 4. University Hospital Mannheim, Mannheim, Germany. 5. Saint Lucas Andreas Hospital, Amsterdam, Netherlands. 6. University of Cincinnati Medical Center, Cincinnati, OH. 7. Case Western Reserve University, Cleveland, OH. 8. University of South Florida College of Medicine, Tampa, FL. 9. Wayne State University, Detroit, MI. 10. Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium. 11. Advanced ENT, Atlanta, GA. 12. University of Pittsburgh School of Nursing, Pittsburgh, PA.
Abstract
OBJECTIVES: To evaluate the long-term (24-mo) effect of cranial nerve upper airway stimulation (UAS) therapy on patient-centered obstructive sleep apnea (OSA) outcome measures. METHODS: Prospective, multicenter, cohort study of 126 patients with moderate to severe OSA who had difficulty adhering to positive pressure therapy and received the surgically implanted UAS system. Outcomes were measured at baseline and postoperatively at 12 mo and 24 mo, and included self- and bedpartner-report of snoring intensity, Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ). Additional analysis included FOSQ subscales, FOSQ-10, and treatment effect size. RESULTS: Significant improvement in mean FOSQ score was observed from baseline (14.3) to 12 mo (17.3), and the effect was maintained at 24 mo (17.2). Similar improvements and maintenance of effect were seen with all FOSQ subscales and FOSQ-10. Subjective daytime sleepiness, as measured by mean ESS, improved significantly from baseline (11.6) to 12 mo (7.0) and 24 mo (7.1). Self-reported snoring severity showed increased percentage of "no" or "soft" snoring from 22% at baseline to 88% at 12 mo and 91% at 24 mo. UAS demonstrated large effect size (> 0.8) at 12 and 24 mo for overall ESS and FOSQ measures, and the effect size compared favorably to previously published effect size with other sleep apnea treatments. CONCLUSIONS: In a selected group of patients with moderate to severe OSA and body mass index ≤ 32 kg/m2, hypoglossal cranial nerve stimulation therapy can provide significant improvement in important sleep related quality-of-life outcome measures and the effect is maintained across a 2-y follow-up period.
OBJECTIVES: To evaluate the long-term (24-mo) effect of cranial nerve upper airway stimulation (UAS) therapy on patient-centered obstructive sleep apnea (OSA) outcome measures. METHODS: Prospective, multicenter, cohort study of 126 patients with moderate to severe OSA who had difficulty adhering to positive pressure therapy and received the surgically implanted UAS system. Outcomes were measured at baseline and postoperatively at 12 mo and 24 mo, and included self- and bedpartner-report of snoring intensity, Epworth Sleepiness Scale (ESS), and Functional Outcomes of Sleep Questionnaire (FOSQ). Additional analysis included FOSQ subscales, FOSQ-10, and treatment effect size. RESULTS: Significant improvement in mean FOSQ score was observed from baseline (14.3) to 12 mo (17.3), and the effect was maintained at 24 mo (17.2). Similar improvements and maintenance of effect were seen with all FOSQ subscales and FOSQ-10. Subjective daytime sleepiness, as measured by mean ESS, improved significantly from baseline (11.6) to 12 mo (7.0) and 24 mo (7.1). Self-reported snoring severity showed increased percentage of "no" or "soft" snoring from 22% at baseline to 88% at 12 mo and 91% at 24 mo. UAS demonstrated large effect size (> 0.8) at 12 and 24 mo for overall ESS and FOSQ measures, and the effect size compared favorably to previously published effect size with other sleep apnea treatments. CONCLUSIONS: In a selected group of patients with moderate to severe OSA and body mass index ≤ 32 kg/m2, hypoglossal cranial nerve stimulation therapy can provide significant improvement in important sleep related quality-of-life outcome measures and the effect is maintained across a 2-y follow-up period.
Authors: T E Weaver; A M Laizner; L K Evans; G Maislin; D K Chugh; K Lyon; P L Smith; A R Schwartz; S Redline; A I Pack; D F Dinges Journal: Sleep Date: 1997-10 Impact factor: 5.849
Authors: Francisco Campos-Rodriguez; Nicolas Peña-Griñan; Nuria Reyes-Nuñez; Ines De la Cruz-Moron; Jose Perez-Ronchel; Francisco De la Vega-Gallardo; Ana Fernandez-Palacin Journal: Chest Date: 2005-08 Impact factor: 9.410
Authors: Terri E Weaver; Greg Maislin; David F Dinges; Thomas Bloxham; Charles F P George; Harly Greenberg; Gihan Kader; Mark Mahowald; Joel Younger; Allan I Pack Journal: Sleep Date: 2007-06 Impact factor: 5.849
Authors: Kingman P Strohl M D; Jonathan Baskin M D; Colleen Lance M D; Diana Ponsky M D; Mark Weidenbecher M D; Madeleine Strohl B A; Motoo Yamauchi M D Journal: Respir Investig Date: 2016-03-18
Authors: Sara Op de Beeck; Andrew Wellman; Marijke Dieltjens; Kingman P Strohl; Marc Willemen; Paul H Van de Heyning; Johan A Verbraecken; Olivier M Vanderveken; Scott A Sands Journal: Am J Respir Crit Care Med Date: 2021-03-15 Impact factor: 21.405